These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 23724409)

  • 21. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
    Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
    Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapagliflozin: BMS 512148; BMS-512148.
    Drugs R D; 2010; 10(1):47-54. PubMed ID: 20509715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
    Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
    Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
    Kilov G; Leow S; Thomas M
    Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
    Handelsman Y
    Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin: more than just another oral glucose-lowering agent?
    Katsiki N; Papanas N; Mikhailidis DP
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1581-9. PubMed ID: 21105857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
    J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(4):263. PubMed ID: 24481146
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Dixit D; Yoon Y; Volino LR; Mansukhani RP
    Am J Health Syst Pharm; 2015 Nov; 72(22):1943-54. PubMed ID: 26541949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
    Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
    Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
    Fioretto P; Giaccari A; Sesti G
    Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
    Jabbour SA; Goldstein BJ
    Int J Clin Pract; 2008 Aug; 62(8):1279-84. PubMed ID: 18705823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
    Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R
    Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dapagliflozin, an SGLT2 inhibitor, for diabetes.
    Hanefeld M; Forst T
    Lancet; 2010 Jun; 375(9733):2196-8. PubMed ID: 20609956
    [No Abstract]   [Full Text] [Related]  

  • 40. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.